Join a conversation with George Clinical Drs. Adrian Liew and Muh Geot Wong covering renal issues particularly prevalent in the Asia-Pacific region. This webinar will discuss how treatment approaches should differ when implementing new global trials in this region, as well as economic hurdles that may impact diagnostic algorithms and standard of care decisions when considering an APAC trial.
Topics for the Conversation:
We hope to see you there.
The session will be streamed live on: October 29 at 8:00 AM ET (USA)
Dr. Adrian Liew is a Senior Consultant Nephrologist and Director of The Kidney and Transplant Practice at Mount Elizabeth Novena Hospital in Singapore. He was the founding Chief of Nephrology at the Department of Renal Medicine in Tan Tock Seng Hospital, Singapore, and was an Associate Professor of Medicine, in charge of the Renal Medicine Curriculum and Clinical OSCEs, with the LKC School of Medicine at the Imperial College London-Nanyang Technological University before moving to his current role.
He is a member of the Executive Committee and elected council member of the International Society of Nephrology (ISN) and chairs the ISN Oceania-Southeast Asia Regional Board and the ISN Renal Disaster Preparedness Working Group. He is also the elected secretary and executive of the International Society for Peritoneal Dialysis and is appointed a member of the KDIGO Guideline working groups for glomerular diseases as well as diabetic kidney disease. His research interests are in glomerular diseases, peritoneal dialysis and diabetic kidney diseases, and is the national leader and steering committee member for various multi-centre clinical trials.
Dr. Wong is Renal Physician at the Royal North Shore hospital, Sydney, Australia. He is also a senior research fellow at the George Institute of Global Health and holds a Senior Lecturer position, Faculty of Medicine, UNSW Sydney. His PhD entitled “Novel therapeutic options in models of nephropathy” was awarded in 2011.
His main area of research is in understanding the pathomechanisms of kidney tubulointerstitial fibrosis and biomarkers in predicting progression of chronic kidney disease particularly in diabetic kidney disease.
Dr. Wong has worked on kidney injury molecule-1, transforming growth factor-β1, bone morphogenetic protein-7, Farnesoid X receptor and novel anti-fibrotic and anti-inflammatory agents in extracellular matrix deposition in human proximal tubular cells and in vivo model of fibrosis.
His is also passionate in translation medicine and is involved in the post hoc analyses of the IDEAL study and currently involved in multicentre international trials at the George Institute including TESTING and SONAR study.
Meet with George Clinical! Contact us to schedule a time now.